117 related articles for article (PubMed ID: 24725126)
41. Neoadjuvant chemotherapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) or cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 69 cases of locally advanced (stage IIIb) breast cancer.
Gupta P; Bijlani L; Rath GK; Misra A; Mishra MC; Shukla NK; Kriplani A; Kapur BM
Jpn J Surg; 1991 Nov; 21(6):637-42. PubMed ID: 1787609
[TBL] [Abstract][Full Text] [Related]
42. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
43. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
44. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
45. Chinese herbal medicines for induction of remission in advanced or late gastric cancer.
Yang J; Zhu L; Wu Z; Wang Y
Cochrane Database Syst Rev; 2013 Apr; (4):CD005096. PubMed ID: 23633324
[TBL] [Abstract][Full Text] [Related]
46. Combined modality treatment of locally advanced breast cancer: adjuvant combination chemotherapy with and without doxorubicin.
Casper ES; Guidera CA; Bosl GJ; Hakes TB; Kaufman RJ; Shurgot B; Kinne DW
Breast Cancer Res Treat; 1987; 9(1):39-44. PubMed ID: 3593990
[TBL] [Abstract][Full Text] [Related]
47. Docetaxel (Taxotere) in combination: a step forward.
Burris HA; Fields S; Peacock N
Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
[TBL] [Abstract][Full Text] [Related]
48. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
Bishop JF; Dewar J; Toner G; Tattersall MH; Olver I; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-5-S17-9. PubMed ID: 9374084
[TBL] [Abstract][Full Text] [Related]
49. Adjuvant docetaxel for node-positive breast cancer.
Martin M; Pienkowski T; Mackey J; Pawlicki M; Guastalla JP; Weaver C; Tomiak E; Al-Tweigeri T; Chap L; Juhos E; Guevin R; Howell A; Fornander T; Hainsworth J; Coleman R; Vinholes J; Modiano M; Pinter T; Tang SC; Colwell B; Prady C; Provencher L; Walde D; Rodriguez-Lescure A; Hugh J; Loret C; Rupin M; Blitz S; Jacobs P; Murawsky M; Riva A; Vogel C;
N Engl J Med; 2005 Jun; 352(22):2302-13. PubMed ID: 15930421
[TBL] [Abstract][Full Text] [Related]
50. [Effect of liu wei di huang or jin gui shen qi decoction as on adjuvant treatment in small cell lung cancer].
Liu XY; Ang NQ
Zhong Xi Yi Jie He Za Zhi; 1990 Dec; 10(12):720-2, 708. PubMed ID: 1963383
[TBL] [Abstract][Full Text] [Related]
51. Exploring the pharmacological mechanism of Yanghe Decoction on HER2-positive breast cancer by a network pharmacology approach.
Zeng L; Yang K
J Ethnopharmacol; 2017 Mar; 199():68-85. PubMed ID: 28130113
[TBL] [Abstract][Full Text] [Related]
52. Treatment of triple-negative breast cancer with Chinese herbal medicine: A prospective cohort study protocol.
Meng H; Peng N; Yu M; Sun X; Ma Y; Yang G; Wang X
Medicine (Baltimore); 2017 Nov; 96(44):e8408. PubMed ID: 29095272
[TBL] [Abstract][Full Text] [Related]
53. Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy.
Blumenschein GR; DiStefano A; Caderao J; Fristenberg B; Adams J; Schweichler LH; Drinkard L
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2633-7. PubMed ID: 10068266
[TBL] [Abstract][Full Text] [Related]
54. Neoadjuvant chemotherapy for Chinese women with locally advanced breast cancer.
Chow LW; Day W; Ng KC
Am Surg; 2001 May; 67(5):412-6. PubMed ID: 11379638
[TBL] [Abstract][Full Text] [Related]
55. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
[TBL] [Abstract][Full Text] [Related]
56. Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.
Clahsen PC; van de Velde CJ; Julien JP; Floiras JL; Delozier T; Mignolet FY; Sahmoud TM
J Clin Oncol; 1996 Mar; 14(3):745-53. PubMed ID: 8622020
[TBL] [Abstract][Full Text] [Related]
57. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
58. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C
Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715
[TBL] [Abstract][Full Text] [Related]
59. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
Alvarez RH; Booser DJ; Cristofanilli M; Sahin AA; Strom EA; Guerra L; Kau SW; Gonzalez-Angulo AM; Hortobagyi GN; Valero V
Cancer; 2010 Mar; 116(5):1210-7. PubMed ID: 20082452
[TBL] [Abstract][Full Text] [Related]
60. [A case of breast cancer patient of CAF (cyclophosphamide, adriamycin, 5-fluorouracil) resistant lung metastasis with remarkable response to reverse drug-resistance by toremifene].
Kusama M; Kaise H; Nakayama S; Ohta D; Aoki T; Koyanagi Y
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1171-5. PubMed ID: 10431584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
